Medically reviewed by Michael MacIntyre, MDSchizophrenia medication falls under two main categories: older, first-generation, or "typical" antipsychotics and newer drugs for schizophrenia known as ...

Digital technology may be on the verge of ‘breaking out’ for schizophrenia treatment, but numerous questions will need to be ...

Currently, the drug clozapine is the only option for treatment-resistant schizophrenia. However, up to 60% of patients don’t respond to it, and it is linked to metabolic issues.

People with schizophrenia will have a new treatment option for the first time in more than three decades, after the Food and Drug Administration Thursday approved a new kind of drug. Studies ...

The U.S. Food and Drug Administration (FDA) on Thursday approved the first new drug to treat people with schizophrenia in more than 30 years. Cobenfy, manufactured by Bristol Myers Squibb, combines ...

A medicine that sidesteps the brain's dopamine receptors to reach different targets represents a new approach to schizophrenia treatment. The Food and Drug Administration approved it Thursday.

Sept. 27, 2024 – In a breakthrough for people living with schizophrenia, the FDA has approved a new oral medication for adults. Unlike traditional antipsychotic drugs, the medication, which will ...

More importantly, the drug could deliver huge value to the healthcare system. In 2019, the economic burden of schizophrenia in America was $343 billion.If Cobenfy can reduce even a fraction of ...

The Food and Drug Administration, as expected, approved KarXT, the first new type of drug for schizophrenia in decades. It appears to be effective, but its main advantage is milder side effects.

From pig kidney transplants to the development of a new schizophrenia drug, here are five of the biggest medical breakthroughs seen in 2024. ABC News. Video. Live. Shows. Shop. Log In. Stream on.

In its submission of the drug for F.D.A. approval, Karuna cited a five-week study of 252 people with schizophrenia, half of whom were given Cobenfy and the other half, a placebo.

The U.S. Food and Drug Administration (FDA) on Thursday approved the first new drug to treat people with schizophrenia in more than 30 years. Cobenfy, manufactured by Bristol Myers Squibb ...